Both recombinant ADA protein and the viral vectored ADA gene are approved in enzyme replacement therapy (ERT) for the treatment of adenosine deaminase deficiency-based severe combined immunodeficiency (SCID), representing an excellent precedent for a favorable safety profile of the ADA enzyme [72,73]. This evidence concerns the gene ADA and severe combined immunodeficiency.